Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?

This article was originally published in PharmAsia News

Executive Summary

In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14
Advertisement

Related Content

China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK
Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK
With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
Advertisement
UsernamePublicRestriction

Register

SC078199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel